Brain Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Brain Cancer, including details on symptoms, benign and malignant tumors, gliomas, treatment.

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.

Pan M, Santamaria M, Wollman DB

Division of Oncology and Hematology, Department of Pathology, Kaiser Permanente Medical Center, Santa Clara, CA, USA. mingui.pan@kp.org

BACKGROUND: A 73-year-old Asian man with a history of lipidemia, hypertension and myocardial infarction presented with dizziness, decreased appetite, weight loss, nonproductive cough and fatigue. His physical performance status was good, and physical examination was unremarkable except for lower-extremity pitting edema. INVESTIGATIONS: Physical examination, brain MRI, CT scans of the chest, abdomen and pelvis, bone scan, CT scan-guided biopsy, hematoxylin and eosin staining, EGFR mutational analysis, and chest X-ray. DIAGNOSIS: Stage IV non-small-cell lung cancer with brain metastasis. MANAGEMENT: Oral erlotinib 150 mg daily for 10 months and ongoing, and whole-brain irradiation.

Published 27 September 2007 in Nat Clin Pract Oncol, 4(10): 603-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Brain Cancer Research Today. All Rights Reserved.